Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.02 from other evidence | 0.00 |
| cell type Human Protein Atlas | group enriched outside the brain (nk-cells) | 0.10 |
| chemistry Open Targets | compounds already reach it: monalizumab | 0.81 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 1 pathway; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 8043
Sealed predictions
- KLRC1 in dopamine neurons, braak+0.21 (p 0.581) → -0.05 (p 0.892)receipt 8050
Swarm cases
receipt 8050: KLRC1 in dopamine neurons, braak
- power
- full sample +0.12 (p 0.646, n 18), 95% CI -0.37 to +0.55. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.17 (p 0.498, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.15 (p 0.561, n 18). could be the mix.
- skeptic
- leave-one-out range -0.02 to +0.21, sign flips 2; without severely affected donors +0.12 (p 0.646, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for KLRC1 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts